Barlas

Review Articles

Cerebral Venous Thrombosis in the Mediterranean Area in Adults. Role of Behet’s Disease as an Underlying Cause

Nilfer Yeşilot Barlas, Glşen Akman-Demir and Sara Zarko Bahar

Istanbul Faculty of Medicine, Department of Neurology, Istanbul University

Correspondence to: Nilufer Yesilot Barlas, Istanbul University, Istanbul Faculty of Medicine, Department of Neurology. Capa 34390, Istanbul-Turkey. Phone: +90 212 4142000/ext: 32572, Fax: +90 212 5334393. E-mail: yesilot@istanbul.edu.tr

Published: October 24, 2011
Received: April 20, 2011
Accepted: October 13, 2011
Mediterr J Hematol  Infect Dis 2011, 3(1): e2011044, DOI 10.4084/MJHID.2011.044
This article is available from: http://www.mjhid.org/article/view/8459
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract
Cerebral venous and dural sinus thrombosis (CVT) is a rare condition with a wide spectrum of clinical presentations. The epidemiology of the disease has evolved considerably during the recent decades with increasing oral contraceptive use in  young and middle-aged women. CVT has various causes including genetic and acquired prothrombotic disorders and it usually has a favorable outcome with a low rate of thrombotic recurrence and mortality. Geographical and ethnic variations between populations may result in different distribution of CVT etiologies leading to different pathophysiological mechanisms and clinical presentations. In CVT series reported mostly from the Americas and the western European countries Behet’s disease (BD) is not reported as a common cause of CVT. However it can be discerned as a frequent cause of CVT in BD series. Due to the high prevalence of BD in the southeast Mediterranean region BD is a frequent cause of CVT in the area. Discerning characteristics of patients with BD and CVT have been reported previously and these might be helpful in guiding diagnosis and treatment of CVT especially in this part of the world.


Cerebral venous and dural sinus thrombosis (CVT) presents with a broad spectrum of symptoms, and it is caused by a variety of etiologies.[1-2] Nearly 85% of CVT cases have a prothrombotic risk factor or a direct causative disorder. These include genetic and acquired prothrombotic disorders, cancer, hematological diseases, pregnancy and puerperium, systemic inflammatory diseases, neurosurgical procedures and some local anatomical causes such as ear, head or neck infections. Around 40% of CVT patients have more than one risk factor.[3] Among the systemic inflammatory disorders, systemic lupus erythematotsus (SLE), antiphospholipid syndrome, sarcoidosis and Behcet’s disease (BD) can be listed.

CVT affects approximately 5 people per million annually.[4] Although underlying factors may be common with other types of venous thromboembolism, the unique way the central nervous system is affected with CVT gives it an exceptional place under the concept of venous thrombosis. Even though CVT can develop in the course of various disorders, due to its clinical presentation most of the patients are evaluated within stroke cohorts. CVT accounts for 0.5 to 1% of all strokes.[2,4] In Istanbul Medical School Stroke Registry CVT comprises 1% of all strokes.[5] It is hard to estimate the number of CVT cases associated with various etiological processes that are not included in stroke registries. The largest information on CVT is provided by International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT) comprised of 624 cases. In that prospective observational study, aimed to determine prognosis of CVT, 624 symptomatic CVT cases from 21 countries were registered over 3 years and ample information about all characteristics of CVT patients were obtained as well.  Fifty-seven percent of these cases are from North-western Mediterranean countries (France, Portugal, Spain and Italy). Overall 74.5% of patients were women and in 2/3rds of them CVT was associated with pregnancy, puerperium, oral contraceptives (OC) or hormone replacement therapy (HRT); factors associated with gender. The second most common etiological factor was thrombophilia with a rate of 34%. However, these figures do not reflect the true underlying factor incidence since in more than 40 % of the cases there was more than one risk factor.

Information on epidemiology and risk factors for cerebral venous thrombosis (CVT) in North-western Mediterranean countries are largely available. On the contrary, information on CVT in the South-eastern Mediterranean region is relatively sparse. The aim of this review is to focus on CVT and inherited and acquired causes in countries of the South-eastern Mediterranean region.

Behcet’s disease is one of the systemic inflammatory diseases with high risk of venous thromboembolism and it is seen more commonly along the Silk Route that extends from the Mediterranean region to Japan.[6] In the South-eastern Mediterranean region etiology of CVT differs compared to Western countries, due to the higher prevalence of Behcet’s disease in the region. Behcet’s disease is a systemic inflammatory disorder of unknown etiology, which presents with recurrent oral aphtae, genital ulcerations, and uveitis. Diagnostic criteria for BD are listed on Table 1.[7] Central nervous system (CNS) involvement is seen about in 5-10% of cases with BD.[8-9] Besides the more commonly encountered parenchymal neurological involvement which occurs mainly as a brainstem meningoencephalitis, intracranial hypertension due to CVT may be seen in about 15% of the patients with neurological involvement. In our series this ratio was 17%, in another series from Tunisia it was 11%.[10-11]




Table 1. Diagnostic criteria for Behet’s disease (International Study Group for Behet’s Disease, 1990)


Although population based studies are lacking from South-eastern Mediterranean countries, a previous study comparing a series of CVT patients with and without BD revealed that more than half of the patients diagnosed with CVT have BD as the underlying factor. [12] When the yearly rate of CVT patients are compared according to etiology in this cohort 42% of the patients had BD as the causative factor compared to all other etiologies complied as a separate group as the underlying conditions for the remaining 58%.[12] One point deserves further clarification because in this study, non-BD group consisted largely of patients that were admitted to the hospital with CVT; however, there may be another group of patients who present with isolated ICH symptoms or only headache that were either not diagnosed as CVT or were diagnosed but managed in the emergency room due to relatively less serious clinical presentation and consequently were not included in the database.

Behcet’s disease comprises a significant portion of CVT cases from many Mediterranean countries, although the percentage varies according to the country, and the center reporting the series. A series from France analyzing isolated intracranial hypertension as the only sign of CVT found that these patients consisted as high as 37% of all CVT patients and 22% of them had BD as the underlying cause; however, this center is one of the dedicated centers to Behcet’s disease in the country. In this cohort other common etiological factors were coagulopathies, unknown etiology, oral contraceptive use and other inflammatory diseases.[13] On the other hand, data from Europe depicts the rarity of BD as an etiological factor of CVT, there were only 6 patients with BD among 624 patients registered in the ISCVT.[3] Interestingly, however, a small CVT series from Lebanon did not have any patients with BD, among 16 cases.[14] This might be reflecting a selection bias, as discussed below.
 
In another CVT series including only patients with cortical or deep vein thrombosis, excluding patients with dural sinus thrombosis from Turkey, similar frequencies of etiologies to those reported from the West with few CVT patients with BD was reported.[15] Albeit small in size, in this series the distribution of etiological factors causing CVT among hormonal factors, malignancy, genetic thrombophilia, infections, hematological disorders, vasculitis and interventions was more or less similar to the largest cohort reported from the rest of the world composed mostly of Nortwestern European countries.[3,15] Most probably, the inclusion of patients with only cortical or deep vein thrombosis was the reason for this difference, supporting the clinical presentation differences in CVT patients with and without BD emphasized in the comparative study.[12] In a previous study of venous thrombosis from Turkey, it was concluded that BD may be taking part together with other etiologies in most of the cases;[16] in that case when another etiology is found BD might have been overlooked in some centers not so familiar with BD. On the other hand, our center is a nationwide tertiary center with a specialized multidisciplinary BD clinic and the frequency of CVT due to BD in our center may be over-represented due to a selection bias. However, the prevalence of BD was estimated as 42/10,000 (95% CI, 34-51/10,000) in Istanbul, Turkey, supporting the notion that Turkey has the highest prevalence rate of the disease in the world.[17] Therefore it is not surprising to encounter BD as a frequent etiology in CVT in the series reported from our center in Istanbul. Furthermore, a recent review including CVT patients with BD mainly from countries in the Mediterranean region showed that CVT incidence in BD was about 3 per 1000 person years.[18]

As mentioned above of the patients in ISCVT were women and the most common risk factor was oral contraceptive use.[3] However, in BD which is slightly more prevalent among males, serious organ involvement is significantly more frequent in males and this gender predisposition is also seen in cerebral venous thrombosis patients with BD.[12] In the study where a direct comparison was made in CVT patients with and without BD, CVT due to BD was significantly more common among male patients. In the same study the mean age was 26 in the non-BD group and 39 in the BD group, resulting in a significant difference. However in the largest CVT series published mean age was 37 for CVT patients, comparable to that seen in BD patients with CVT.[3]

The rarity of acute presentation with neurological deficits and seizures in patients with BD may preclude the inclusion of these patients in other CVT series.[7] In CVT clinical features differ according to the location and the extent of the occlusion in the sinuses and veins and the course of the underlying disease process. A slowly progressing dural sinus thrombosis that does not affect the cortical venous circulation may present with isolated headache and normal neurological examination findings. These patients may be misdiagnosed as pseudotumor cerebri. However an acute clinical presentation with focal neurological deficits and seizures can be readily diagnosed as CVT with appropriate imaging techniques. CVT in BD patients mostly presents with signs of isolated intracranial hypertension and venous infarction rarely develops.[12] As a consequence in CVT due to BD patients usually have an insidious onset, they present usually with headache as the only symptom and the neurological examination is normal or only papilledema or lateral gaze paresis indicative of intracranial hypertension is found. 

In the past, CVT used to be considered a condition with bad prognosis, but currently CVT is considered to be a relatively more benign condition with mortality rates below 10%.[19-23] According to the limited follow-up data on CVT with and without BD there were no significant differences between the two groups on outcome.12 A greater tendency for recurrence was found in patients with BD.[12] A cytopathological study on BD CVT cases is not available however former autopsy findings on pulmonary arterial thrombosis suggests an inflammatory process underlying the thrombosis.[24] This finding may explain the chronic course of the thrombotic process in CVT due to BD leading to the mentioned clinical differences.

The treatment of CVT mainly comprises of anticoagulation, with subcutaneous fractionated heparin at the acute stage, and 6 months of oral anticoagulation, afterwards.[25] However, since the thrombosis of BD is considered an inflammatory process rather than a procoagulant process,[26] treatment of these cases may vary. Although treatment of CVT due to BD is still debated and Class I evidence is lacking[27] our approach is to use only steroids, instead of anticoagulants, as also suggested by EULAR task force.[28] In such cases we usually give 5 consecutive days of IV methylprednisolone followed by a slow oral taper.[29] In recent years we also tend to add long-term azathioprine to prevent recurrences or other vascular complications that could be seen in those patients.[27] In intractable cases or repetitive CVTs due to BD, anticoagulants may be added to steroids; but anticoagulants should never be used alone.[29] It should be kept in mind that pulmonary aneurysms should be ruled out before initiating any anticoagulant treatment in patients with BD.

Due to the scarcity of data on CVT and inherited and acquired causes in countries of the south-eastern Mediterranean region a comparison with northwestern Mediterranean region is quite difficult to make. However, one report emphasized the occurrence of CVT due to BD in Turkey which deserves attention both in terms of the differences in demographic and clinical features and possibly the treatment options. Therefore, in patients with CVT from southeast Mediterranean region, BD should be kept in mind especially if the patient is male, and if no other risk factor can be identified. BD should always be questioned since multi-etiology cases are not very rare. A multi-national and multi-center prospective analysis of the CVT cases in south-east Mediterranean region seems to be worthwhile in the near future.



References
  
  1. Stam J. Thrombosis of the cerebral veins and sinuses. N Engl J Med. 2005 Apr 28;352(17):1791-8. http://dx.doi.org/10.1056/NEJMra042354 PMid:15858188 
  2. Bousser MG, Ferro JM. Cerebral venous thrombosis: an update. Lancet Neurol. 2007 Feb;6(2):162-70. http://dx.doi.org/10.1016/S1474-4422(07)70029-7 
  3. Ferro JM, Canhao P, Stam J, Bousser MG, Barinagarrementeria F. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke. 2004 Mar;35(3):664-70. http://dx.doi.org/10.1161/01.STR.0000117571.76197.26 PMid:14976332 
  4. Saposnik G, Barinagarrementeria F, Brown RD, Jr., Bushnell CD, Cucchiara B, Cushman M, et al. Diagnosis and Management of Cerebral Venous Thrombosis: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2011 Feb 3. 
  5. N. Yesilot BAK, R. Tuncay, O. Coban and S. Z. Bahar. Gender differences in acute stroke: Istanbul Medical School Stroke Registry. Neurology India. [Original Article]. 2011;59(2):24-9. 
  6. Siva A, Altintas A, Saip S. Behcet's syndrome and the nervous system. Curr Opin Neurol. 2004 Jun;17(3):347-57. http://dx.doi.org/10.1097/00019052-200406000-00017 PMid:15167071 
  7. Criteria for diagnosis of Behcet's disease. International Study Group for Behcet's Disease. Lancet. 1990 May 5;335(8697):1078-80. PMid:1970380 
  8. Serdaroglu P, Yazici H, Ozdemir C, Yurdakul S, Bahar S, Aktin E. Neurologic involvement in Behcet's syndrome. A prospective study. Arch Neurol. 1989 Mar;46(3):265-9. PMid:2919979 
  9. Siva A, Kantarci OH, Saip S, Altintas A, Hamuryudan V, Islak C, et al. Behcet's disease: diagnostic and prognostic aspects of neurological involvement. J Neurol. 2001 Feb;248(2):95-103. http://dx.doi.org/10.1007/s004150170242 PMid:11284141 
  10. Akman-Demir G, Serdaroglu P, Tasci B. Clinical patterns of neurological involvement in Behcet's disease: evaluation of 200 patients. The Neuro-Behcet Study Group. Brain. 1999 Nov;122 (Pt 11):2171-82. http://dx.doi.org/10.1093/brain/122.11.2171 PMid:10545401 
  11. Houman MH, Neffati H, Braham A, Harzallah O, Khanfir M, Miled M, et al. Behcet's disease in Tunisia. Demographic, clinical and genetic aspects in 260 patients. Clin Exp Rheumatol. 2007 Jul-Aug;25(4 Suppl 45):S58-64.  
  12. Yesilot N, Bahar S, Yilmazer S, Mutlu M, Kurtuncu M, Tuncay R, et al. Cerebral venous thrombosis in Behcet's disease compared to those associated with other etiologies. J Neurol. 2009 Jul;256(7):1134-42. http://dx.doi.org/10.1007/s00415-009-5088-4 PMid:19280104 
  13. Biousse V, Ameri A, Bousser MG. Isolated intracranial hypertension as the only sign of cerebral venous thrombosis. Neurology. 1999 Oct 22;53(7):1537-42. PMid:10534264 
  14. Otrock ZK, Taher AT, Shamseddeen WA, Mahfouz RA. Thrombophilic risk factors among 16 Lebanese patients with cerebral venous and sinus thrombosis. J Thromb Thrombolysis. 2008 Aug;26(1):41-3. http://dx.doi.org/10.1007/s11239-007-0093-x PMid:17823778 
  15. Sagduyu A, Sirin H, Mulayim S, Bademkiran F, Yunten N, Kitis O, et al. Cerebral cortical and deep venous thrombosis without sinus thrombosis: clinical MRI correlates. Acta Neurol Scand. 2006 Oct;114(4):254-60. http://dx.doi.org/10.1111/j.1600-0404.2006.00595.x PMid:16942545 
  16. Gul A, Aslantas AB, Tekinay T, Konice M, Ozcelik T. Procoagulant mutations and venous thrombosis in Behcet's disease. Rheumatology (Oxford). 1999 Dec;38(12):1298-9. http://dx.doi.org/10.1093/rheumatology/38.12.1298 PMid:10587567 
  17. Azizlerli G, Kose AA, Sarica R, Gul A, Tutkun IT, Kulac M, et al. Prevalence of Behcet's disease in Istanbul, Turkey. Int J Dermatol. 2003 Oct;42(10):803-6. http://dx.doi.org/10.1046/j.1365-4362.2003.01893.x PMid:14521694 
  18. Aguiar de Sousa D, Mestre T, Ferro JM. Cerebral venous thrombosis in Behcet's disease: a systematic review. J Neurol. 2011 Jan 6. 
  19. Dentali F, Ageno W. Cerebral vein thrombosis. Intern Emerg Med. 2010 Feb;5(1):27-32. http://dx.doi.org/10.1007/s11739-009-0329-1 PMid:19949894 
  20. Dentali F, Gianni M, Crowther MA, Ageno W. Natural history of cerebral vein thrombosis: a systematic review. Blood. 2006 Aug 15;108(4):1129-34. http://dx.doi.org/10.1182/blood-2005-12-4795 PMid:16609071 
  21. Breteau G, Mounier-Vehier F, Godefroy O, Gauvrit JY, Mackowiak-Cordoliani MA, Girot M, et al. Cerebral venous thrombosis 3-year clinical outcome in 55 consecutive patients. J Neurol. 2003 Jan;250(1):29-35. http://dx.doi.org/10.1007/s00415-003-0932-4 PMid:12527989 
  22. Preter M, Tzourio C, Ameri A, Bousser MG. Long-term prognosis in cerebral venous thrombosis. Follow-up of 77 patients. Stroke. 1996 Feb;27(2):243-6. http://dx.doi.org/10.1161/01.STR.27.2.243 PMid:8571417 
  23. Deschiens MA, Conard J, Horellou MH, Ameri A, Preter M, Chedru F, et al. Coagulation studies, factor V Leiden, and anticardiolipin antibodies in 40 cases of cerebral venous thrombosis. Stroke. 1996 Oct;27(10):1724-30. http://dx.doi.org/10.1161/01.STR.27.10.1724 PMid:8841318 
  24. Hamuryudan V, Er T, Seyahi E, Akman C, Tuzun H, Fresko I, et al. Pulmonary artery aneurysms in Behcet syndrome. Am J Med. 2004 Dec 1;117(11):867-70. http://dx.doi.org/10.1016/j.amjmed.2004.05.027 PMid:15589493 
  25. Einhaupl K, Stam J, Bousser MG, De Bruijn SF, Ferro JM, Martinelli I, et al. EFNS guideline on the treatment of cerebral venous and sinus thrombosis in adult patients. Eur J Neurol. 2010 Oct;17(10):1229-35. http://dx.doi.org/10.1111/j.1468-1331.2010.03011.x PMid:20402748 
  26. Yazici H. Behcet's syndrome: an update. Curr Rheumatol Rep. 2003 Jun;5(3):195-9. http://dx.doi.org/10.1007/s11926-003-0066-9 PMid:12744810 
  27. Saadoun D, Wechsler B, Resche-Rigon M, Trad S, Le Thi Huong D, Sbai A, et al. Cerebral venous thrombosis in Behcet's disease. Arthritis Rheum. 2009 Apr 15;61(4):518-26. http://dx.doi.org/10.1002/art.24393 
  28. Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, et al. EULAR recommendations for the management of Behcet disease. Ann Rheum Dis. 2008 Dec;67(12):1656-62. http://dx.doi.org/10.1136/ard.2007.080432 PMid:18245110 
  29. Akman-Demir G SS, Siva A. Behcet’s disease. Current Treatment Options in Neurology. 2011 Jun;13(3):290-310. 



Abstract views:
594

Views:
PDF
102
HTML
726

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


Copyright (c) 2016 Mediterranean Journal of Hematology and Infectious Diseases

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

 

The Mediterranean Journal of Hematology and Infectious Diseases [eISSN 2035-3006] is owned by the U.C.S.C. and it is published by PAGEPress®, Pavia, Italy. All credits and honors to PKP for their OJS.
 
 
© PAGEPress 2008-2017     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185